Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
National Heart, Lung, and Blood Institute (NHLBI) |
---|---|
Information provided by: | National Heart, Lung, and Blood Institute (NHLBI) |
ClinicalTrials.gov Identifier: | NCT00005356 |
To investigate hemostatic variables in relation to cardiovascular risk in the Framingham Offspring Study cohort.
Condition |
---|
Cardiovascular Diseases Heart Diseases Death, Sudden, Cardiac Myocardial Infarction Thrombosis Atherosclerosis Carotid Artery Diseases |
Study Type: | Observational |
Study Design: | Natural History |
Study Start Date: | July 1994 |
Estimated Study Completion Date: | May 1998 |
BACKGROUND:
Elevation of platelet reactivity plasminogen activator inhibitor, fibrinogen, von Willebrand's factor, and factor VII have been reported to increase myocardial infarction risk. Myocardial infarction and sudden cardiac death are more frequent in the morning when platelet activity is increased and fibrinolysis is decreased. Reduction of recurrent myocardial infarction by aspirin and coumadin suggests causal roles for platelet activity and coagulation. Increases in viscosity and decreases in anti-thrombin III and Protein C have been linked with increased thrombosis. Despite these findings, a coherent picture of these disparate hemostatic indices as cardiac risk factors has yet to emerge.
DESIGN NARRATIVE:
Platelet reactivty, plasminogen activatator inhibitor, fibrinogen, von Willebrand's factor, factor VII, and other hemostatic risk factors were measured in all 4,000 subjects of the Framingham Offspring Study. The data were combined with the regularly collected Framingham data to: determine the relationships between hemostatic factors and carotid atherosclerosis as assessed by ultrasound; determine the relationship between hemostatic factors and the traditional cardiac risk factors; and determine if hemostatic risk factors independently predict myocardial infarction and cardiac death.
Genders Eligible for Study: | Male |
Accepts Healthy Volunteers: | No |
No eligibility criteria
Study ID Numbers: | 4242 |
Study First Received: | May 25, 2000 |
Last Updated: | June 23, 2005 |
ClinicalTrials.gov Identifier: | NCT00005356 History of Changes |
Health Authority: | United States: Federal Government |
Atherosclerosis Arterial Occlusive Diseases Death Heart Diseases Myocardial Ischemia Vascular Diseases Central Nervous System Diseases Heart Arrest Ischemia Arteriosclerosis Brain Diseases |
Cerebrovascular Disorders Hemostatics Thrombosis Embolism and Thrombosis Necrosis Embolism Death, Sudden Death, Sudden, Cardiac Carotid Artery Diseases Infarction Myocardial Infarction |
Atherosclerosis Arterial Occlusive Diseases Death Heart Diseases Myocardial Ischemia Nervous System Diseases Vascular Diseases Central Nervous System Diseases Heart Arrest Ischemia Arteriosclerosis Brain Diseases |
Cerebrovascular Disorders Thrombosis Embolism and Thrombosis Necrosis Pathologic Processes Death, Sudden Cardiovascular Diseases Death, Sudden, Cardiac Carotid Artery Diseases Infarction Myocardial Infarction |